Authors

John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine

Latest:

Next Steps in Mantle Cell Lymphoma

John P. Leonard, MD, Weill Cornell Medical Center

John P. O’Bryan, PhD

Latest:

Novel Protein May Provide Tool to Target Elusive RAS Oncogene

Given the "addiction" of many tumors to mutant RAS for their survival, there has been renewed interest in developing new ways to inhibit RAS in cancer.

John P. Sfakianos, MD

Latest:

Dr. Sfakianos on the Utility of Adjuvant Therapy in Bladder Cancer Management

John P. Sfakianos, MD, discusses the utility of adjuvant therapy in bladder cancer management.

John Pagel, MD, PhD, Swedish Cancer Institute

John Primrose, MD, ChB, FRCP

Latest:

Dr. Primrose on Adjuvant Capecitabine For Biliary Tract Cancer

John Primrose, MD, ChB, FRCS, professor of medicine/surgery, University of Southampton, United Kingdom, discusses the impact of adjuvant capecitabine in patients with biliary tract cancer.

John R. Horn, PharmD, FCCP

Latest:

Drug Interactions With Tyrosine Kinase Inhibitors

Tyrosine Kinase Inhibitors (TKIs) are indicated for the treatment of a variety of malignancies, due to their ability to interfere with cell communication and growth. This review focuses on interactions that affect TKI metabolism.

John Rhee, MD

Latest:

The Importance of Mentoring in Preparing the Next Generation of Oncologists

Since the time of Hippocrates, practicing the art of medicine has involved the passage of knowledge and experience from one generation of practitioners to the next.

John Robertson, MD

Latest:

Dr. Robertson on Subgroup Analysis of the FALCON Trial for HR+ Breast Cancer

John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant (Faslodex) versus anastrozole (Arimidex) in patients with HR-positive advanced breast cancer.

John S. Banerji, MD, MCh (urology)

Latest:

Never Say Die

Through this eventful journey, I have experienced stark contrasts.

John S. Kuo, MD, PhD, FAANS, FACS

Latest:

Patient-Derived Cancer Stem Cells Offer Diagnostic and Therapeutic Potential in Brain Cancer

A brain tumor research group at the UW Carbone Cancer Center focuses on biological studies of patient-derived glioblastoma multiforme (GBM) cancer stem cells, combined with analysis of patient-matched serum-cultured GBM and an annotated GBM tissue microarray, to identify clinically relevant biomarkers.

John Strickler, MD

Latest:

Dr Strickler on the Rationale for Evaluating Telisotuzumab Adizutecan in Gastric/GEJ Cancer

John H. Strickler, MD, details the rationale for evaluating telisotuzumab adizutecan in advanced gastric/GEJ cancer.

John Sweetenham, MD

Latest:

Dr. Sweetenham on Unanswered Questions With CAR T-Cell Therapy in Pediatric ALL

John Sweetenham, MD, associate director for clinical affairs, Harold G. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses unanswered questions with CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

John T. Comerci, MD

Latest:

Dr. Comerci on the Use of Laparoscopy in Ovarian Cancer

John T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, University of Pittsburgh Medical Center Passavant Hospital, discusses the use of laparoscopy in ovarian cancer.

John V. Heymach, MD, PhD

Latest:

Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC

John V. Heymach, MD, PhD, discusses the efficacy of mobocertinib in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

John V. Heymach, MD, PhD, MD Anderson Cancer Center

Latest:

Second-Line Treatment of SCLC

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

John W. Longshore, PhD, Carolinas Pathology Group

Latest:

Dr. Longshore on Comprehensive Vs Single-Gene Molecular Testing in Lung Cancer

John Longshore, PhD, FACMG, discusses selecting between comprehensive vs single-gene molecular testing in lung cancer.

John Wagstaff, MD

Latest:

Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer

John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

John Yarnold, MBBS

Latest:

Dr. Yarnold on Hypofractionation in the START Trials

John Yarnold, MBBS, from The Institute of Cancer Research in London, discusses results from the START trials that examined hypofractionated radioatherapy for women with early breast cancer.

John Zoidis, MD

Latest:

VTE in Cancer Patients: New Guidelines Define Role of Anticoagulants

Blood clots and their complications are a major cause of death in cancer patients, and affect up to 20% of persons with cancer at some point in their treatment.